Patent · US Active

Single domain antibodies capable of modulating BACE activity

US10377834B2 · kind B2 · utility

3Cited by

7References

9Claims

0Family size

Assignees

VIB VZW · BE
Katholieke Universiteit Leuven, KU LEUVEN R&D · BE
VRIJE UNIVERSITEIT BRUSSEL · BE

Inventors

Bart De Strooper · Leuven, BE
Els Marjaux · Tienen, BE
Lujia Zhou · Leuven, BE
Serge Muyldermans · Sint-Genesius-Rode, BE

Key dates

Filing date	Jan 16, 2018
Grant date	Aug 13, 2019
Priority date	—
Expiry date	Jan 16, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.